Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
The Dana-Farber Brigham Cancer Center team of breast cancer experts is dedicated to improving clinical care and advancing research for patients with ductal carcinoma in situ (DCIS). Our physician-scientists are engaged in multiple research studies to
better understand the risk of progression to invasive disease, and to better tailor treatment options to meet the needs of patients with DCIS.
Patients at Dana-Farber Brigham Cancer Center have access to leading-edge research and the opportunity to join clinical trials. Your team will discuss whether a clinical trial may be right for you. Together, we will advance the understanding of DCIS in
order to provide more personalized treatment and prevention strategies for patients now and in the future.
Trial 18-075: A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly-diagnosed ductal carcinoma in situ Principal Investigator: Judy E. Garber, MD, MPH
This study looks at the potential role of the medication DUAVEE in preventing DCIS from developing into an invasive cancer. Patients opting into the study will be asked to take a medication for approximately one month prior to surgery. The research team
will collect breast tissue from your biopsy and your surgical specimen to look for changes in the DCIS cells.
Trial 17-131: Comparison of operative to monitoring and endocrine therapy (COMET) trial for low-risk DCIS: A phase III prospective randomized trial Principal Investigator: Anna Weiss, MD
This study examines the likelihood of progression from DCIS to invasive breast cancer in women with low-risk DCIS who undergo either watchful waiting (no surgery) or standard care (surgery).
New Patient Appointments